Literature DB >> 26143268

Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.

Jeffrey J Raizer1, Karan S Dixit.   

Abstract

OPINION STATEMENT: Treating patients with brain tumors can be divided into tumor-directed therapies, the management of tumor-related symptoms and complications and the psychosocial aspect of patient care. In this review, we will discuss the management of disease and treatment-related complications, which can negatively impact patient quality of life and functional status. Brain edema is a common complication or brain tumors and often causes more symptoms than the tumor itself. Treatment options are limited to the use of corticosteroids, which although effective have a plethora of side effects, so the goal should be the lowest dose that maximizes symptoms. Seizures are more common in lower grade brain tumors and treatment should be limited to patients who have seizures using agents that do not affect the metabolism of other drugs, especially chemotherapies. Blood clots are also common in patients and although there is a "fear" of tumoral bleeding, this is not a frequent occurrence; hence, using anticoagulants should be routinely used in patients who experience this complication.

Entities:  

Mesh:

Year:  2015        PMID: 26143268     DOI: 10.1007/s11864-015-0357-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  52 in total

1.  PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Authors:  J R Perry; J A Julian; N J Laperriere; W Geerts; G Agnelli; L R Rogers; M G Malkin; R Sawaya; R Baker; A Falanga; S Parpia; T Finch; M N Levine
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

Review 2.  Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention.

Authors:  T K LaPier
Journal:  J Cardiopulm Rehabil       Date:  1997 Mar-Apr       Impact factor: 2.081

Review 3.  Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.

Authors:  Melanie S M van Breemen; Erik B Wilms; Charles J Vecht
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

Review 4.  Corticosteroid-use in primary and secondary brain tumour patients: a review.

Authors:  Richella Ryan; Sara Booth; Stephen Price
Journal:  J Neurooncol       Date:  2011-10-05       Impact factor: 4.130

5.  Corticosteroid toxicity in neuro-oncology patients.

Authors:  D E Weissman; D Dufer; V Vogel; M D Abeloff
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

6.  Steroid-induced weakness in patients with primary brain tumors.

Authors:  E J Dropcho; S J Soong
Journal:  Neurology       Date:  1991-08       Impact factor: 9.910

Review 7.  Management of venous thromboembolism in patients with primary and metastatic brain tumors.

Authors:  David E Gerber; Stuart A Grossman; Michael B Streiff
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

8.  Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases.

Authors:  Gladys Alvarado; Rahat Noor; Roland Bassett; Nicholas E Papadopoulos; Kevin B Kim; Wen-Jen Hwu; Agop Bedikian; Sapna Patel; Patrick Hwu; Michael A Davies
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

Review 9.  The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy C Ryken; Michael McDermott; Paula D Robinson; Mario Ammirati; David W Andrews; Anthony L Asher; Stuart H Burri; Charles S Cobbs; Laurie E Gaspar; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

10.  Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.

Authors:  Daniel A Lim; Phiroz Tarapore; Edward Chang; Marlene Burt; Lenna Chakalian; Nicholas Barbaro; Susan Chang; Kathleen R Lamborn; Michael W McDermott
Journal:  J Neurooncol       Date:  2009-01-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.